Teva Pharmaceuticals Industries Ltd (NYSE:TEVA) has agreed to a $450 million settlement with the U.S. government to resolve allegations that they violated the Anti-Kickback Statute (AKS) and the False Claims Act (FCA).
The settlement stems from claims that Teva engaged in two unlawful kickback schemes, impacting Medicare and the pricing of essential drugs.
Also Read: Eli Lilly Fights $183M Medicaid Fraud Judgment, Cites Reasonable Interpretation Of Medicaid Rules.
This resolution includes $225 million in criminal penalties that Teva USA previously paid as part of a deferred prosecution agreement with the Department of Justice.
The first kickback scheme involved allegations that Teva violated the ...
